Management Team

Elran Haber, PhD, MBA, Chief Executive Officer

Elran Haber, PhD, MBA

Chief Executive Officer

Dr. Haber serves as Biomica’s Chief Executive Officer. Prior to joining Biomica Dr. Haber served as Therapix Biosciences (Nasdaq, TASE: TRPX) CEO leading the company to a successful IPO on Nasdaq and advancing the Company's programs to clinical stage.
Dr. Haber spent more than 10 years as Chairman and board member of several privately held, and publicly traded companies. Dr. Haber has served in senior executive roles in various life science companies and a private investment firm.
Dr. Haber holds a PhD in Pharmaceutical Science and an MBA in Finance & Financial Engineering, both from The Hebrew University of Jerusalem, Israel

Prof. Yehuda Ringel, Chief Scientific Officer

Prof. Yehuda Ringel

Chief Scientific Officer

Chief of the Gastroenterology and Hepatology Division of the Meir Medical Center in Israel; Adjunct Professor of Medicine at Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, USA

Prof. Ringel has more than 30 years of diverse experiences, especially in Gastroenterology and translational research, and is an expert on IBS and functional motility disorders; he serves as an editor and in editorial boards of prestigious Scientific Journals. Prof. Ringel is Recipient of several prestigious awards. He received his medical degree from Technion Institute of Technology, Israel.

Shiri Meshner, PhD, VP of Research & Development

Shiri Meshner, PhD

VP of Research & Development

Dr. Meshner spent over 5 years working in the pharma industry both in the US and in Israel (OSI pharmaceuticals and Teva pharmaceuticals) and previously served as the head & principal investigator of the Dead Sea microbiology lab in the Dead Sea-Arava Science Center.

She holds a PhD in systems microbiology from the Department of Physics of Complex Systems at The Weizmann Institute.

Board

Ofer Haviv, Chairman

Ofer Haviv

Chairman

Ofer Haviv holds the position of Evogene’s (Nasdaq: EVGN) President and CEO as of late 2004. Prior to that he held the positions of company COO and CFO from 2002 to 2004 and was involved in Evogene’s spin-off from Compugen in 2002. At Compugen, he held the position of Director of Finance and Treasurer of Compugen (NASDAQ: CGEN) for four years, during which time the company completed two private placements and an IPO on NASDAQ
Mr. Haviv holds a B.A. degree in Economics and Accounting from Faculty of Management, Tel Aviv University and is a Certified Public Accountant in Israel.

Prof. Yehuda Ringel, Director

Prof. Yehuda Ringel

Director

Chief of the Gastroenterology and Hepatology Division of the Meir Medical Center in Israel; Adjunct Professor of Medicine at Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, USA
Prof. Ringel has more than 30 years of diverse experiences, especially in Gastroenterology and translational research, and is an expert on IBS and functional motility disorders; he serves as an editor and in editorial boards of prestigious Scientific Journals. Prof. Ringel is Recipient of several prestigious awards. He received his medical degree from Technion Institute of Technology, Israel.

Doron Ben Ami, Director

Doron Ben Ami

Director

Doron is a seasoned executive with more than 20 years of management experience in the biotech industry.
He is the founder and managing director of Triticum, a startup company that is developing a clot retriever device for the treatment of stroke and occlusions in peripheral vessels.
He previously held a range of executive positions including Associate Vice President for the Eastern European and Israel region at Merck (MSD), Managing Director of the Merck subsidiary in Israel, and General Manager of Lundbeck Israel.
Doron also acts as a consultant to several pharma and medical device companies.
Holds a Master of Health Systems Administration degree (M.H.A.) from Tel Aviv University, Israel.

Kinneret Savitsky, PhD, Director

Kinneret Savitsky, PhD

Director

Dr. Kinneret Livnat-Savitzky is the CEO of FutuRx Ltd., the Israeli Biotechnology accelerator that was established in January 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation, JJDC and Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc. after winning the tender of the Office of the Israeli Innovation Authority (IIA) in Israel.
Prior to joining FutuRx, Kinneret served as the CEO of BioLineRX and Vice President of Biology of Compugen Ltd. Kinneret brings significant experience in different aspects of drug discovery and development, deal making and fund-raising.
Dr. Livnat-Savitzky holds a PhD from the Tel-Aviv University

Scientific Advisory Board & Advisors

Prof. Yehuda Ringel,

Prof. Yehuda Ringel

Chief of the Gastroenterology and Hepatology Division of the Meir Medical Center in Israel; Adjunct Professor of Medicine at Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, USA
Prof. Ringel has more than 30 years of diverse experiences, especially in Gastroenterology and translational research, and is an expert on IBS and functional motility disorders; he serves as an editor and in editorial boards of prestigious Scientific Journals. Prof. Ringel is Recipient of several prestigious awards. He received his medical degree from Technion Institute of Technology, Israel.

Prof. Willem M De Vos,

Prof. Willem M De Vos

Prof. Willem M De Vos is Professor and Chair of Microbiology at Wageningen University, the Netherlands and Professor of Human Microbiomics at the University of Helsinki, Finland, where he also served as Finland Distinguished and Academy Professor. He supervised over 100 PhD students, is a member of the Royal Netherlands Academy of Arts and Sciences, and various academic and industry boards. He has (co) authored over 700 peer-reviewed papers, was involved in the filing of more than 50 patents or patent applications., and received many international scientific, honorary and royal awards.

Prof. R. Balfour Sartor,

Prof. R. Balfour Sartor

Prof. R. Balfour Sartor serves as the Midget Distinguished Professor of Medicine, Microbiology and Immunology and Director of the Multidisciplinary IBD Center at the University of North Carolina, Chapel Hill. In addition he has served, as Chief Medical Advisor to the Crohn's and Colitis Foundation, where he now directs the Litwin Pioneers grants program and is a nationally and internationally recognized authority on host- microbial interactions, mucosal immunology and inflammatory bowel diseases

Prof. James Versalovic,

Prof. James Versalovic

Prof. James Versalovic, Pathologist-In-Chief at Texas Children’s Hospital and Director of Texas Children’s Microbiome Center, Professor and Vice Chair of Pathology & Immunology at Baylor College of Medicine, a Professor of Molecular and Human Genetics, Molecular Virology & Microbiology, and Pediatrics. Prof. Versalovic created the first pediatric microbiome center and the first therapeutic microbiology fellowship program in the US. He served as Editor-in-Chief of the Manual of Clinical Microbiology and has authored more than 160 primary manuscripts and received notable awards.

Prof. David Rubin,

Prof. David Rubin

David T. Rubin, MD, is a renowned gastroenterologist who specializes in the treatment and assessment of digestive diseases. His clinical expertise includes inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) and high-risk cancer syndromes.
Dr. Rubin performs clinical research related to outcomes in inflammatory bowel diseases, with particular interest in prevention of cancer associated with these gastrointestinal diseases. He is also interested in new therapies for inflammatory bowel diseases, better screening tools for colorectal cancer, and the genetics of inflammatory bowel diseases.

Dr. Ravid Straussman,

Dr. Ravid Straussman

Dr. Ravid Straussman, is the Principle investigator of the Tumor microenvironment, tumor microbiome and resistance to anti-cancer therapy lab at the Weizmann Institute of Science, Israel. Straussman's lab focuses on understanding the roles of the tumor microenvironment and the tumor microbiome in resistance to cytotoxic, targeted, and immune mediated anti-cancer therapies. Straussman holds an MD/ PhD from the Hebrew University Hadassah Medical School and completed a Post-doc training at the Broad Institute of Harvard and MIT.